A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy

PHASE2CompletedINTERVENTIONAL
Enrollment

274

Participants

Timeline

Start Date

July 19, 2021

Primary Completion Date

February 17, 2022

Study Completion Date

March 4, 2022

Conditions
Acute Pain
Interventions
DRUG

VX-548

Tablets for oral administration.

DRUG

HB/APAP

Capsules for oral administration.

DRUG

Placebo (matched to VX-548)

Placebo matched to VX-548 for oral administration.

DRUG

Placebo (matched to HB/APAP)

Placebo matched to HB/APAP for oral administration.

Trial Locations (12)

21122

Chesapeake Research Group, Pasadena

30331

Atlanta Center for Medical Research, Atlanta

35660

Shoals Medical Trials Inc., Sheffield

45417

Midwest Clinical Research Center, Dayton

75006

Legent Orthopedic Hospital, Carrollton

77401

First Surgical Hospital, Bellaire

78229

Endeavor Clinical Trials, San Antonio

84107

JBR Clinical Research, Salt Lake City

85053

Arizona Research Center, Phoenix

91105

Lotus Clinical Research, Pasadena

91356

New Hope Research Development, Tarzana

92801

Anaheim Clinical Trials, Anaheim

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT04977336 - A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy | Biotech Hunter | Biotech Hunter